The role of interleukin-1 beta in the pathophysiology of Schnitzler’s syndrome. Homo sapiens

Schnitzler’s syndrome (SchS) is a disabling autoinflammatory disorder, characterized by chronic urticaria a chronic urticarial rash, an M-protein, arthralgia, and other signs of systemic inflammation. Anti-interleukin-1 (IL-1) beta antibodies are highly effective, but the pathophysiology is still largely unknown. Here we studied the effect of in-vivo IL-1 inhibition on serum markers of inflammation and cellular immune responses. Overall design: Transcriptome analysis of RNA from PBMCs from three patients with Schnitzler’s syndrome and three matched controls. Patient samples were drawn during symptomatic disease, anakinra and canakinumab treatment.